Jj. Killion et Ij. Fidler, THERAPY OF CANCER METASTASIS BY TUMORICIDAL ACTIVATION OF TISSUE MACROPHAGES USING LIPOSOME-ENCAPSULATED IMMUNOMODULATORS, Pharmacology & therapeutics, 78(3), 1998, pp. 141-154
The therapy of cancer requires strategies that can eradicate metastati
c disease. Metastases consist of unique subpopulations of tumor cells
that are able to colonize distant organs and become autonomous from ho
meostatic mechanisms. Conventional therapies generally have been unsuc
cessful due to biological heterogeneity in metastatic tumors. It is po
ssible to circumvent this heterogeneity by the tumoricidal activation
of tissue macrophages. Activation can be achieved by encapsulation of
immunomodulators, e.g., muramyl tripeptide analogues, into liposomes,
and this form of immunomodulation leads to eradication of established
tumor metastases in numerous animal tumor models. Modulation of the tu
mor microenvironment by activated macrophages may prove to be an addit
ional modality in therapy that combines the use of biological response
modifiers with conventional therapies. (C) 1998 Elsevier Science Inc.